AAPL340.42+3.75 (+1.11%) ▲|ABBV272.42+1.06 (+0.39%) ▲|ABT98.49-0.24 (-0.24%) ▼|ACN208.36+11.72 (+5.96%) ▲|ADBE241.05+8.28 (+3.56%) ▲|AMAT509.57-11.08 (-2.13%) ▼|AMD620.68-25.18 (-3.90%) ▼|AMGN407.44-5.64 (-1.37%) ▼|AMT166.73+0.55 (+0.33%) ▲|AMZN254.06-5.86 (-2.25%) ▼|AVGO360.14-16.37 (-4.35%) ▼|AXP308.10+3.85 (+1.27%) ▲|BA187.75-0.57 (-0.30%) ▼|BAC53.61+0.09 (+0.17%) ▲|BKNG159.97+4.10 (+2.63%) ▲|BLK1,065.35-4.28 (-0.40%) ▼|BMY59.58-0.12 (-0.20%) ▼|BNY143.61+0.89 (+0.62%) ▲|BRK-B511.05+4.80 (+0.95%) ▲|C128.08+0.76 (+0.60%) ▲|CAT796.18-17.65 (-2.17%) ▼|CL88.10+0.89 (+1.02%) ▲|CMCSA21.21+0.27 (+1.29%) ▲|COF199.40+3.49 (+1.78%) ▲|COP134.19+4.35 (+3.35%) ▲|COST947.92+5.67 (+0.60%) ▲|CRM227.80+3.24 (+1.44%) ▲|CSCO114.89-2.50 (-2.13%) ▼|CVS87.80-0.15 (-0.17%) ▼|CVX211.55+6.40 (+3.12%) ▲|DE652.58-4.29 (-0.65%) ▼|DHR217.46-1.03 (-0.47%) ▼|DIS107.02+2.27 (+2.17%) ▲|DUK116.84+1.34 (+1.16%) ▲|EMR159.06-0.16 (-0.10%) ▼|FDX291.73+2.69 (+0.93%) ▲|GD329.90+3.27 (+1.00%) ▲|GE305.62+2.00 (+0.66%) ▲|GEV999.35+2.26 (+0.23%) ▲|GILD147.10+0.25 (+0.17%) ▲|GM82.25+1.26 (+1.56%) ▲|GOOG344.86-2.51 (-0.72%) ▼|GOOGL348.29-2.21 (-0.63%) ▼|GS882.59-4.62 (-0.52%) ▼|HD295.47+9.70 (+3.39%) ▲|HON206.60-1.51 (-0.73%) ▼|IBM226.61+6.10 (+2.77%) ▲|INTC107.08-6.04 (-5.34%) ▼|INTU303.88+8.02 (+2.71%) ▲|ISRG415.41+0.89 (+0.21%) ▲|JNJ256.48-1.97 (-0.76%) ▼|JPM331.42+1.84 (+0.56%) ▲|KO87.77+1.95 (+2.27%) ▲|LIN481.70-2.28 (-0.47%) ▼|LLY1,169.60-19.12 (-1.61%) ▼|LMT507.89+8.67 (+1.74%) ▲|LOW188.85+7.31 (+4.03%) ▲|LRCX320.59-8.92 (-2.71%) ▼|MA574.76+4.70 (+0.82%) ▲|MCD236.90+6.02 (+2.61%) ▲|MDLZ60.67+1.29 (+2.17%) ▲|MDT87.75+2.24 (+2.62%) ▲|META720.89-0.42 (-0.06%) ▼|MMM163.58+1.46 (+0.90%) ▲|MO71.42+2.04 (+2.94%) ▲|MRK142.38-0.41 (-0.29%) ▼|MS187.44-2.27 (-1.20%) ▼|MSFT522.61-7.15 (-1.35%) ▼|MU1,035.84-52.16 (-4.79%) ▼|NEE77.37+0.31 (+0.40%) ▲|NFLX71.57+1.87 (+2.68%) ▲|NKE34.74+0.38 (+1.11%) ▲|NOW139.75+1.88 (+1.36%) ▲|NVDA230.48-6.99 (-2.94%) ▼|ORCL135.69-7.87 (-5.48%) ▼|PEP128.34+4.61 (+3.73%) ▲|PFE27.82-0.18 (-0.64%) ▼|PG150.59+2.77 (+1.87%) ▲|PLTR198.78+4.66 (+2.40%) ▲|PM200.50+7.81 (+4.05%) ▲|QCOM176.01-1.11 (-0.63%) ▼|RTX184.32+4.06 (+2.25%) ▲|SBUX93.21-0.37 (-0.40%) ▼|SCHW96.87+1.29 (+1.35%) ▲|SO86.15+0.71 (+0.83%) ▲|SPG199.61+2.02 (+1.02%) ▲|T24.87+0.40 (+1.63%) ▲|TMO651.98-10.08 (-1.52%) ▼|TMUS171.31+3.66 (+2.18%) ▲|TSLA375.00-2.81 (-0.74%) ▼|TXN288.20-0.78 (-0.27%) ▼|UBER70.24+1.79 (+2.62%) ▲|UNH370.95-5.03 (-1.34%) ▼|UNP278.20+3.52 (+1.28%) ▲|UPS94.13+1.84 (+1.99%) ▲|USB57.03+0.86 (+1.53%) ▲|V375.10+3.00 (+0.81%) ▲|VZ46.35+0.58 (+1.27%) ▲|WFC82.03+1.77 (+2.21%) ▲|WMT110.56+2.40 (+2.22%) ▲|XOM168.50+4.45 (+2.71%) ▲|AAPL340.42+3.75 (+1.11%) ▲|ABBV272.42+1.06 (+0.39%) ▲|ABT98.49-0.24 (-0.24%) ▼|ACN208.36+11.72 (+5.96%) ▲|ADBE241.05+8.28 (+3.56%) ▲|AMAT509.57-11.08 (-2.13%) ▼|AMD620.68-25.18 (-3.90%) ▼|AMGN407.44-5.64 (-1.37%) ▼|AMT166.73+0.55 (+0.33%) ▲|AMZN254.06-5.86 (-2.25%) ▼|AVGO360.14-16.37 (-4.35%) ▼|AXP308.10+3.85 (+1.27%) ▲|BA187.75-0.57 (-0.30%) ▼|BAC53.61+0.09 (+0.17%) ▲|BKNG159.97+4.10 (+2.63%) ▲|BLK1,065.35-4.28 (-0.40%) ▼|BMY59.58-0.12 (-0.20%) ▼|BNY143.61+0.89 (+0.62%) ▲|BRK-B511.05+4.80 (+0.95%) ▲|C128.08+0.76 (+0.60%) ▲|CAT796.18-17.65 (-2.17%) ▼|CL88.10+0.89 (+1.02%) ▲|CMCSA21.21+0.27 (+1.29%) ▲|COF199.40+3.49 (+1.78%) ▲|COP134.19+4.35 (+3.35%) ▲|COST947.92+5.67 (+0.60%) ▲|CRM227.80+3.24 (+1.44%) ▲|CSCO114.89-2.50 (-2.13%) ▼|CVS87.80-0.15 (-0.17%) ▼|CVX211.55+6.40 (+3.12%) ▲|DE652.58-4.29 (-0.65%) ▼|DHR217.46-1.03 (-0.47%) ▼|DIS107.02+2.27 (+2.17%) ▲|DUK116.84+1.34 (+1.16%) ▲|EMR159.06-0.16 (-0.10%) ▼|FDX291.73+2.69 (+0.93%) ▲|GD329.90+3.27 (+1.00%) ▲|GE305.62+2.00 (+0.66%) ▲|GEV999.35+2.26 (+0.23%) ▲|GILD147.10+0.25 (+0.17%) ▲|GM82.25+1.26 (+1.56%) ▲|GOOG344.86-2.51 (-0.72%) ▼|GOOGL348.29-2.21 (-0.63%) ▼|GS882.59-4.62 (-0.52%) ▼|HD295.47+9.70 (+3.39%) ▲|HON206.60-1.51 (-0.73%) ▼|IBM226.61+6.10 (+2.77%) ▲|INTC107.08-6.04 (-5.34%) ▼|INTU303.88+8.02 (+2.71%) ▲|ISRG415.41+0.89 (+0.21%) ▲|JNJ256.48-1.97 (-0.76%) ▼|JPM331.42+1.84 (+0.56%) ▲|KO87.77+1.95 (+2.27%) ▲|LIN481.70-2.28 (-0.47%) ▼|LLY1,169.60-19.12 (-1.61%) ▼|LMT507.89+8.67 (+1.74%) ▲|LOW188.85+7.31 (+4.03%) ▲|LRCX320.59-8.92 (-2.71%) ▼|MA574.76+4.70 (+0.82%) ▲|MCD236.90+6.02 (+2.61%) ▲|MDLZ60.67+1.29 (+2.17%) ▲|MDT87.75+2.24 (+2.62%) ▲|META720.89-0.42 (-0.06%) ▼|MMM163.58+1.46 (+0.90%) ▲|MO71.42+2.04 (+2.94%) ▲|MRK142.38-0.41 (-0.29%) ▼|MS187.44-2.27 (-1.20%) ▼|MSFT522.61-7.15 (-1.35%) ▼|MU1,035.84-52.16 (-4.79%) ▼|NEE77.37+0.31 (+0.40%) ▲|NFLX71.57+1.87 (+2.68%) ▲|NKE34.74+0.38 (+1.11%) ▲|NOW139.75+1.88 (+1.36%) ▲|NVDA230.48-6.99 (-2.94%) ▼|ORCL135.69-7.87 (-5.48%) ▼|PEP128.34+4.61 (+3.73%) ▲|PFE27.82-0.18 (-0.64%) ▼|PG150.59+2.77 (+1.87%) ▲|PLTR198.78+4.66 (+2.40%) ▲|PM200.50+7.81 (+4.05%) ▲|QCOM176.01-1.11 (-0.63%) ▼|RTX184.32+4.06 (+2.25%) ▲|SBUX93.21-0.37 (-0.40%) ▼|SCHW96.87+1.29 (+1.35%) ▲|SO86.15+0.71 (+0.83%) ▲|SPG199.61+2.02 (+1.02%) ▲|T24.87+0.40 (+1.63%) ▲|TMO651.98-10.08 (-1.52%) ▼|TMUS171.31+3.66 (+2.18%) ▲|TSLA375.00-2.81 (-0.74%) ▼|TXN288.20-0.78 (-0.27%) ▼|UBER70.24+1.79 (+2.62%) ▲|UNH370.95-5.03 (-1.34%) ▼|UNP278.20+3.52 (+1.28%) ▲|UPS94.13+1.84 (+1.99%) ▲|USB57.03+0.86 (+1.53%) ▲|V375.10+3.00 (+0.81%) ▲|VZ46.35+0.58 (+1.27%) ▲|WFC82.03+1.77 (+2.21%) ▲|WMT110.56+2.40 (+2.22%) ▲|XOM168.50+4.45 (+2.71%) ▲|
15.2 C
New York
Friday, October 9, 2026

Tag: information

newssourceFORcompanyinformationcontent1releasesmarket

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Scatec signs PPA for 900MW onshore wind project in Egypt

Oslo/Cairo, 15 June 2025: Scatec ASA, a leading renewable energy solutions provider, has signed a USD-denominated 25-year Power Purchase Agreement (PPA) with the Egyptian Electricity Transmission Company (EETC) for a 900 MW wind project, through its dedicated project company “Shadwan Wind Power SAE” to accelerate Egypt’s transition towards a greener and more sustainable energy mix.

EQT sets target fund size for EQT XI at EUR 23 billion

THIS IS INFORMATION THAT EQT AB (PUBL) IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SUBMITTED FOR...

Redtiger Celebrates 5 Years of Bestselling Dash Cams for Cars With Discounts, Giveaways, and More

Marking five years of empowering drivers and vehicle owners to keep themselves and their passengers safe on the road, Redtiger is celebrating the anniversary with...

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap

TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch now just weeks away. With over $4.5 million already raised and more than 11,500 participants onboard, momentum is surging.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

KIWI design Celebrates One Million Head Straps Sold, Redefines VR Comfort with Series Made for Meta Products

LOS ANGELES, June 15, 2025 /PRNewswire/ -- KIWI design, a pioneer in VR accessories, announced surpassing one million head strap sales, delivering enhanced comfort...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInformation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers